FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax for Newly Diagnosed AML
esmo - Evidence for efficacy is based on the results from the Study ASTX727-07
AI Summary: The FDA has approved an oral combination (decitabine/cedazuridine plus venetoclax) as a treatment option for newly diagnosed acute myeloid leukemia patients who are older or unfit for intensive therapy. The approval offers an at-home alternative to frequent infusions, potentially reducing clinic visits and improving convenience for a vulnerable population.
Related Stories
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 20 days
Datroway secures regulatory approvals in breast cancer across US and EU / 13 days
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 24 days
FDA grants early access to experimental pancreatic cancer drug / 4 wks
FDA approves relacorilant plus nab‑paclitaxel for resistant ovarian cancers / 7 wks
FDA flags misleading cancer drug claims tied to biotech billionaire / 2 months
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 6 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Research Funding, Health IT, Medical Devices, Medicaid and look for the RSS link.
StackHealth Time Machine